Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.69 |
| ▸ | MAOB | P27338 | 7/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045256 | 0.98 | KDM1A (0.67) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045062 | 0.97 | KDM1A (0.64) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045243 | 0.94 | KDM1A (0.73) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045251 | 0.92 | KDM1A (0.70) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045247 | 0.91 | KDM1A (0.68) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045067 | 0.88 | KDM1A (0.65) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL23309057 | 0.88 | KDM1A (0.54) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045254 | 0.87 | KDM1A (0.64) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL10045253 | 0.85 | KDM1A (0.61) | KDM1AMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL12913969 | 0.82 | KDM1A (0.73) | KDM1AMAOBHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186391-B2 | Cyclic peptide inhibitors of lysine-specific demethylase 1 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186391-B2 | Cyclic peptide inhibitors of lysine-specific demethylase 1 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150065434-A1 | CYCLIC PEPTIDE INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065434-A1 | CYCLIC PEPTIDE INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-03-05 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | KDM1A 1/4885MAOB 857/4885HDAC3 572/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | KDM1A 1/4885MAOB 857/4885HDAC3 572/4885 |
| US-20150065434-A1 | CYCLIC PEPTIDE INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 | KDM1A, KDM1B, JMJD6 | KDM1A 1/4885MAOB 2947/4885HDAC3 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.